ESCMID/ASM Conference on

Drug Development to Meet the Challenge of Antimicrobial Resistance

Vienna, Austria
21 – 23 September 2016
Organizing Committee
David Hooper, Boston, USA
William Hope, Liverpool, United Kingdom
Gunnar Kahlmeter, Växjö, Sweden
Ursula Theuretzbacher, Vienna, Austria

Programme Committee
David Andes, Madison, USA
Marco Cavaleri, London, United Kingdom
Ed Cox, Silver Spring, USA
George Drusano, Lake Nona, USA
William Hope, Liverpool, United Kingdom
Gunnar Kahlmeter, Växjö, Sweden
Jason Roberts, Brisbane, Australia
Keith Rodvold, Chicago, USA
Ursula Theuretzbacher, Vienna, Austria

Conference Objectives
Background: Antimicrobial drug resistance is an urgent problem. There are relatively few agents in developmental pipelines. Traditional pathways for drug development are expensive and slow. Both the EMA and FDA have recognized some of these obstacles for drug development. New regulation now enables accelerated drug development, with adaptive licensing until larger definitive phase III studies are completed. Such an approach enables access to drugs for patients with unmet medical needs.

Challenges: There is uncertainty regarding what constitutes reasonable pathways for accelerated drug development. There is a reliance on very robust preclinical studies, innovative clinical trial design, strong academic-industrial partnerships, and a requirement for early engagement with regulatory bodies.

Scientific Secretariat
Nora Nedkov
ESCMID Executive Office
P.O. Box 214
4010 Basel, Switzerland
Phone +41 61 508 01 52
Fax +41 61 508 01 51
vienna2016@escmid.org

www.escmid.org/Vienna2016